1Hammerschlag MR.Use of cethromycin,a new ketolide,for treatment of community-acquired respiratory infections[J].Expert Opin Investig Drugs,2008,17(3):387-400.
2Hamilton JM.Activity of ketolide (cethromycin) against erythromycin-resistant Streptococcus pneumoniae:correlation with extended MLSK phenotypes[J].J Antimicrob Chemother,2002,50(6):907-913.
3Jorgensen JH,Crawford SA,McEImeel ML,et al.Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae[J].Antimicrob Agents Chemother,2004,48(2):605-607.
4Azoulay DE.Efficacy of cethromycin,a new ketolide,against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model[J].Antimicrob Agents Chemother,2006,50(9):3033-3038.
5Cao Z,Zhong P,Ruan X,et al.Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae[J].Int J Antimicrob Agents,2004,24(4):362-368.
7Hammerschlag MR.Microbiological efficacy of ABT-773(cethromycin)for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae[J].J Antimicrob Chemother,2003,51(4):1025-1028.
8Pletz MW.ABT-773:pharmacokinetics and interactions with ranitidine and sucralfate[J].Antimicrob Agents Chemother,2003,47(3):1129-1131.
